SVB Leerin

An SVB Leerink genetic medicine analyst is bullish on shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Here's why.  The Intellia Analyst: SVB Leerink analyst Mani Foroohar, M.D. reiterated an Outperform rating on Intellia and increased his price target from $81 to $159. The Intellia...